Evidence map›Paper›PMID 33505141›Full record

ArticleWorld journal of gastroenterology2020

Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients

Yang Li, Zhong-Xin Li, Chen-Yang Xie, Jing Fan, Ji Lv, Xin-Jian Xu, Jian Lv, Wen-Tao Kuai, Yi-Tao Jia

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Apigenin 7-glucoside reprograms tumor metabolism and enhances immunotherapy efficacy in colorectal cancer via DLX5.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yang LiDepartment of Oncology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
Zhong-Xin LiSecond Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Chen-Yang XieSecond Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Jing FanDepartment of Oncology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
Ji LvDepartment of Surgery, The First Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei Province, China.
Xin-Jian XuDepartment of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Jian LvDepartment of Emergency, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
Wen-Tao KuaiDepartment of Oncology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
Yi-Tao JiaDepartment of Oncology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China. jiayitao99@163.com.
Hebei General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously showed, using the Traditional Chinese Medicine System Pharmacology Database, that Gegen Qinlian decoction (GQD) had a direct antitumor effect, and was combined with programmed cell death protein (PD)-1 inhibitors to treat microsatellite stable (MSS) tumor-bearing mice. However, the effect of GQD on patients with colorectal cancer (CRC) is not clear.

aimTo determine the therapeutic mechanism of GQD in improving immune function, reducing inflammation and protecting intestinal barrier function.

methodsSeventy patients with CRC were included in this study: 37 in the control group and 33 in the treatment group. The proportions of CD4

resultsThere were no adverse events in the treatment group. The proportion of CD4

conclusionGQD enhances immunity and protects intestinal barrier function in patients with CRC by regulating the composition of gut microbiota.

Indexed as

Colorectal NeoplasmsDrugs, Chinese HerbalGastrointestinal MicrobiomeAnimalsHumansMedicine, Chinese TraditionalMiceDrugs, Chinese HerbalgegenqinlianColorectal cancerGegen Qinlian decoctionGut microbiotaImmunityInflammationIntestinal barrier function

Identifiers

PMID33505141
PMCPMC7789057
OpenAlexW3115238585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.